Efficacy and Tolerability of the PET-Guided Program BrECADD for Advanced Stages of Classical Hodgkin Lymphoma: Data from the Real-World Setting in Russia

BACKGROUND. In 2024, the German Hodgkin Study Group (GHSG) published the unprecedented results of the HD21 trial on PET-guided program BrECADD for patients with advanced stages of classical Hodgkin lymphoma (cHL) showing the highest cure probability with the best tolerability.

AIM. To review and analyze the first experience in Russia with BrECADD administered to patients with advanced stages of cHL in a real-world setting.

MATERIALS & METHODS. Clinical data from 20 BrECADD recipients with advanced stages of newly diagnosed cHL were provided by 5 medical institutions from 3 cities in Russia. The median age was 31.5 years (range 19–43 years), there were 13 (65 %) female patients. PET/CT after 2 cycles (PET-2) was performed in 9 patients, 6 (66.6 %) of them showed complete metabolic response, which is similar to the results of the HD21 trial (64 %). PET-guided therapy was administered to only 5 patients (25 %), while in the rest of them the number of BrECADD cycles was determined by the attending physician regardless of whether an interim PET-2 was performed and irrespective of its results: 16 patients received 4 and 4 patients received 6 BrECADD cycles. Consolidating radiotherapy was administered to 4 cHL patients.

RESULTS. After the chemotherapy stage, complete metabolic response was achieved in 16 (84 %) out of 19 patients (1 patient in clinical remission refused PET after chemotherapy completion), which is similar to the results of the HD21 trial (82 %), partial remission was identified in 1 and disease progression was observed in 2 patients. With the follow-up of 17.5 months, all patients were alive, progression-free survival was 90 % by that time. There were no cases of cycle or dose reduction due to adverse events. Increasing the intervals between cycles in 1/3 patients did not affect general therapy outcomes.

CONCLUSION. The analysis of the first findings on BrECADD demonstrated its high efficacy, moderate toxicity, and feasibility in a real-world setting in Russia. The main issue appeared to be non-compliance with the HD21 recommendations in the majority of cases, that requires further standardization in the implementation of the program with a view to establishing best practices and identifying lessons learned with BrECADD administration in the routine practice of treating advanced cHL stages.

• Elena Andreevna Demina NI Pirogov National Medical and Surgical Center, 70 Nizhnyaya Pervomaiskaya ul., Moscow, Russian Federation, 105203 https://orcid.org/0000-0002-0318-9051 (unauthenticated)
• O.S. Samoilova NA Semashko Nizhny Novgorod Regional Clinical Hospital, 190 Rodionova ul., Nizhny Novgorod, Russian Federation, 603093
• A.V. Halturin NI Pirogov National Medical and Surgical Center, 70 Nizhnyaya Pervomaiskaya ul., Moscow, Russian Federation, 105203 https://orcid.org/0009-0005-9399-9590 (unauthenticated)
• O.M. Malchuk NA Semashko Nizhny Novgorod Regional Clinical Hospital, 190 Rodionova ul., Nizhny Novgorod, Russian Federation, 603093
• V.O. Sarzhevskiy NI Pirogov National Medical and Surgical Center, 70 Nizhnyaya Pervomaiskaya ul., Moscow, Russian Federation, 105203 https://orcid.org/0000-0001-7164-6595 (unauthenticated)
• A.A. Samoylova NI Pirogov National Medical and Surgical Center, 70 Nizhnyaya Pervomaiskaya ul., Moscow, Russian Federation, 105203 https://orcid.org/0000-0002-3876-3869 (unauthenticated)
• G.S. Tumyan NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 https://orcid.org/0000-0002-5771-4413 (unauthenticated)
• A.A. Semenova NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 https://orcid.org/0000-0003-4951-3053 (unauthenticated)
• A.F. Saidullaeva Tver Regional Clinical Oncology Dispensary, 57/37 15 let Oktyabrya ul., Tver, Russian Federation, 170008
• K.D. Kaplanov SP Botkin Moscow Multispecialty Research Clinical Center, 5 2-i Botkinskii pr-d, Moscow, Russian Federation, 125284 https://orcid.org/0000-0001-6574-0518 (unauthenticated)
• N.E. Mochkin NI Pirogov National Medical and Surgical Center, 70 Nizhnyaya Pervomaiskaya ul., Moscow, Russian Federation, 105203 https://orcid.org/0000-0001-5622-0828 (unauthenticated)
• N.S. Shorokhov NI Pirogov National Medical and Surgical Center, 70 Nizhnyaya Pervomaiskaya ul., Moscow, Russian Federation, 105203 https://orcid.org/0000-0003-4442-289X (unauthenticated)
• Yu.V. Protopopova NI Pirogov National Medical and Surgical Center, 70 Nizhnyaya Pervomaiskaya ul., Moscow, Russian Federation, 105203 https://orcid.org/0000-0001-8960-6241 (unauthenticated)
• V.Ya. Melnichenko NI Pirogov National Medical and Surgical Center, 70 Nizhnyaya Pervomaiskaya ul., Moscow, Russian Federation, 105203 https://orcid.org/0000-0002-6728-6264 (unauthenticated)

1. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с. [Kaprin A.D., Starinskii V.V., Shakhzadova A.O., eds. Zlokachestvennye novoobrazovaniya v Rossii v 2019 godu (zabolevaemost’ i smertnost’). (Malignant neoplasms in Russia in 2019: incidence and mortality.) Moscow: MNIOI im. P.A. Gertsena — filial FGBU “NMITs radiologii” Publ.; 2020. 252 p. (In Russ)]
2. Демина Е.А., Тумян Г.С., Унукова Е.Н. и др. Современные возможности лечения первичных больных лимфомой Ходжкина и причины неудач лечения. Онкогематология. 2007;2:24–30. doi: 10.17650/1818-8346-2007-0-2-24-30. [Demina E.A., Tumyan G.S., Unukova E.N., et al. Modern treatment programs for primary Hodgkin’s lymphoma and reasons of treatment failure. Oncohematology. 2007;2:24–30. doi: 10.17650/1818-8346-2007-0-2-24-30. (In Russ)]
3. DeVita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73(6):881–95. doi: 10.7326/0003-4819-73-6-881. DOI: https://doi.org/10.7326/0003-4819-73-6-881
4. DeVita VT, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980;92(5):587–95. doi: 10.7326/0003-4819-92-5-587. DOI: https://doi.org/10.7326/0003-4819-92-5-587
5. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252–9. doi: 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7. DOI: https://doi.org/10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7
6. Loeffler M, Hasenclever D, Diehl V. Model based development of the BEACOPP regimen for advanced stage Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group. Ann Oncol. 1998;9(Suppl 5):S73–8. doi: 10.1093/annonc/9.suppl_5.s73. DOI: https://doi.org/10.1093/annonc/9.suppl_5.S73
7. Diehl V. Dose-escalation study for the treatment of Hodgkin’s disease. The German Hodgkin Study Group (GHSG). Ann Hematol. 1993;66(3):139–40. doi: 10.1007/BF01697624. DOI: https://doi.org/10.1007/BF01697624
8. Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: Interim report from a trial of the German Hodgkin Study Group. J Clin Oncol. 1998;16(12):3810–21. doi: 10.1200/jco.1998.16.12.3810. DOI: https://doi.org/10.1200/JCO.1998.16.12.3810
9. Kreissl S, Müller H, Goergen H, et al. Health-related quality of life in patients with Hodgkin lymphoma: a longitudinal analysis of the German Hodgkin Study Group. J Clin Oncol. 2020;38(25):2839–48. doi: 10.1200/jco.19.03160. DOI: https://doi.org/10.1200/JCO.19.03160
10. Connors JM. Hodgkin’s lymphoma — the great teacher. N Engl J Med. 2011;365(3):264–5. doi: 10.1056/nejme1104576. DOI: https://doi.org/10.1056/NEJMe1104576
11. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9. doi: 10.1200/JCO.2011.38.0410. DOI: https://doi.org/10.1200/JCO.2011.38.0410
12. Eichenauer DA, Plütschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18(12):1680–7. doi: 10.1016/S1470-2045(17)30696-4. DOI: https://doi.org/10.1016/S1470-2045(17)30696-4
13. Damaschin C, Goergen H, Kreissl S, et al. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group. Leukemia. 2022;36(2):580–2. doi: 10.1038/s41375-021-01386-z. DOI: https://doi.org/10.1038/s41375-021-01386-z
14. Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024;404(10450):341–52. doi: 10.1016/s0140-6736(24)01315-1. DOI: https://doi.org/10.1016/S0140-6736(24)01404-1
15. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390(10114):2790–802. doi: 10.1016/s0140-6736(17)32134-7. DOI: https://doi.org/10.1016/S0140-6736(17)32134-7
16. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68. doi: 10.1200/jco.2013.54.8800. DOI: https://doi.org/10.1200/JCO.2013.54.8800
17. Kreissl S, Goergen H, Müller H, et al. Survivors’ perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group. Leuk Lymphoma. 2019;60(5):1389–98. doi: 10.1080/10428194.2018.1540781. DOI: https://doi.org/10.1080/10428194.2018.1540781
18. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Hodgkin Lymphoma Version 2.2025. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439 (accessed 01.12.2025).
19. European Medicines Agency. Adcetris — opinion on variation to marketing authorisation. Available from: https://www.ema.europa.eu/en/medicines/human/variation/adcetris-0 (accessed 01.12.2025).